HeartBeam Secures New Patents to Strengthen 3D ECG Technology Portfolio

HeartBeam Inc. (NASDAQ: BEAT) has strengthened its intellectual property portfolio with the acquisition of two new U.S. patents, marking significant progress in its 3D ECG technology development. The company now holds more than 20 U.S. and international patents, with additional applications pending, solidifying its position in the cardiac monitoring technology sector. These patents enhance HeartBeam's ability to deliver powerful, personalized insights into heart health through its innovative platform.

The technology focuses on making cardiac monitoring and diagnosis more accessible outside traditional medical facilities. HeartBeam CEO Robert Eno emphasized that the new patents enable the company to expand the reach and impact of its groundbreaking 3D ECG technology, contributing to the transformation of cardiac care. The company is developing the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions, designed for use in portable devices that provide actionable heart intelligence wherever the patient is located.

This advancement allows physicians to identify cardiac health trends and acute conditions outside medical facilities, directing patients to appropriate care and redefining cardiac health management. The company's growing patent portfolio, which includes 13 U.S. and 4 international issued patents related to technology enablement, supports its vision of providing powerful cardiac insights through portable technology. For more information about HeartBeam's developments, visit https://www.HeartBeam.com.

The latest news and updates relating to HeartBeam are available through specialized communications platforms focusing on biotechnology and biomedical sciences. BioMedWire, part of the Dynamic Brand Portfolio at IBN, provides comprehensive distribution services including access to wire solutions, article syndication to over 5,000 outlets, press release enhancement, and social media distribution to millions of followers. For detailed terms of use and disclaimers applicable to all content, visit https://www.BioMedWire.com/Disclaimer.